Eli Lilly’s tirzepatide shows promising results in MASH treatment study
Eli Lilly and Company (NYSE: LLY) revealed compelling outcomes from the SYNERGY-NASH study, showcasing significant efficacy of tirzepatide in treating metabolic dysfunction-associated steatohepatitis (MASH) with ... Read More
Lilly announces promising updates on olomorasib in KRAS G12C-mutant cancers at ASCO 2024
Eli Lilly and Company (Lilly, NYSE: LLY) has released updated data from its ongoing Phase 1/2 clinical trial for olomorasib, showcasing significant advancements in the ... Read More
Eli Lilly completes $1.04bn acquisition of Prevail Therapeutics to expand gene therapy program
Eli Lilly and Company has officially finalized its acquisition of Prevail Therapeutics in a deal valued at up to $1.04 billion. This acquisition represents a ... Read More
Lilly to launch real-world Covid-19 study of bamlanivimab in New Mexico
Eli Lilly and Company (Lilly), a global leader in the pharmaceutical industry, has announced plans to conduct a new pragmatic study of its experimental Covid-19 ... Read More
Eli Lilly completes $8bn acquisition of Loxo Oncology to expand oncology portfolio
Eli Lilly and Company, the US-based pharmaceutical giant, has finalised its $8 billion acquisition of Connecticut-based biopharmaceutical firm Loxo Oncology, a move expected to significantly ... Read More
Lilly to acquire Loxo Oncology in $8bn deal: A game-changer in precision cancer treatment
Eli Lilly and Company (Lilly), a global leader in pharmaceuticals, has made headlines with its announcement to acquire Loxo Oncology, a pioneering biopharmaceutical company based ... Read More
Eli Lilly’s Emgality gets FDA green light for migraine prevention
Eli Lilly and Company has secured approval from the US Food and Drug Administration (FDA) for its migraine drug Emgality (galcanezumab-gnlm) as a preventative therapy ... Read More
Lilly completes acquisition of immuno-oncology firm Armo BioSciences
Strategic Expansion in Cancer Treatment: Eli Lilly and Company (Lilly), a leading US pharmaceutical firm, has finalized its acquisition of Armo BioSciences, a California-based immuno-oncology ... Read More
Eli Lilly’s Cyramza fails to improve survival in gastric cancer trial despite meeting initial goal
In a recent announcement, Eli Lilly and Company disclosed that its phase 3 RAINFALL trial of the drug Cyramza (ramucirumab) for the treatment of HER2-negative ... Read More
FDA approves Eli Lilly’s Verzenio for metastatic breast cancer treatment
Eli Lilly and Company (Lilly) has announced receiving U.S. Food and Drug Administration (FDA) approval for Verzenio (abemaciclib), to treat patients with metastatic breast cancer ... Read More